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Case Report
Introduction
Ventricular septal defect (VSD) that occurs after acute 
myocardial infarction (AMI) is a rare event, with an incidence 
reported in the literature from 0.2% to 0.34% of the cases1. The 
treatment of choice is surgical correction, and if not performed 
earlier, with due support (especially the implantation of intra-
aortic balloon in cases of cardiogenic shock2,3), the disease has 
a mortality rate above 90%1,3,4.
In turn, the appropriate surgical treatment of VSD still 
results in high mortality rates, which vary in current series 
20% to 87%4 .
More recently it has been proposed as an alternative 
method, less invasive than surgery, closure of VSD after 
AMI with percutaneous technique by occlusion devices3,5. 
In most reports and case series in the literature evaluating its 
use in the context of AMI, we used the Amplatzer® septal 
occluder (AGA Medical Corporation, Plymouth, MN, USA)3,5. 
Currently, other prostheses are available, such as prostheses 
CERA made of nitinol with ceramic coating layers and ePTFE 
mesh. In this sense, we report the first case of percutaneous 
closure of VSD after AMI conducted in our country with the 
use of this prosthesis.
Case Report
Male patient, 55 years, white, with previous hypertension, 
dyslipidemia, and smoker (40 years. pack). He developed 
chest pain at rest and exertion, of recent onset (five weeks), 
associated with dyspnea. Chest radiography showed an enlarged 
cardiac silhouette, and it was sent for echocardiography, which 
showed an ejection fraction (LVEF) = 65%, although akinesia 
of the anteroseptal wall. The clinical treatment was optimized 
and it was requested myocardial perfusion scintilography with 
pharmacological stress, which showed persistent uptake in the 
inferior wall (apical portion) and the anteroseptal wall with mild 
transient component, and LVEF of 40%.
Consequently, coronary angiography was performed, which 
demonstrated the Left Anterior Descending artery (LAD) 
occluded in the medium third, receiving collateral circulation 
grade I of the Right Coronary Artery (RCA), circumflex artery 
with obstruction of 70% in its distal third; RCA without 
obstructive injuries. On the left ventriculography, in addition to 
moderate anterior hypocontractility and anteroseptal akinesia, it 
was observed muscular VSD near the ventricular apex (Figure 1). 
That same day, a new echocardiogram confirmed the muscular 
VSD with about 5 mm and L/R shunt.
The patient was then referred to our hospital, two weeks after 
diagnosis of VSD, maintaining some degree of dyspnea (NYHA 
class II). We promoted a discussion (clinician, interventionalist 
and cardiac surgeon) and due to the not indication for CABG 
(very narrow distal bed of LAD) and anatomy of VSD favorable 
for percutaneous closure (muscular VSD near the cardiac apex, 
about 5 mm edges diameter and> 5 mm), we opted for the 
correction of the VSD with the use of percutaneous prosthesis.
The procedure for closure of the VSD was successful, through 
the implantation of prosthesis CERA muscular type No. 10 
driven by transthoracic echocardiography and angiography. This 
device for muscular VSD is made of a mesh of ultra-fine wires 
of nitinol with polyester patches in the inner portion (ePTFE)6, 
composed of two discs connected by a central waist length of 
7 mm (Figure 2). In addition, the prosthesis mesh, screw and 
hub are coated with nanostructures of ceramic, which prevent 
direct contact of nitinol (nickel-containing) in the blood. This 
prosthesis is self-expansible and self-centered, being implanted 
by low-profile system that allows rescuing it and reposition it at 
any time before its final release from the delivery cable (Figure 
2). All these devices are registered on the National Health 
Surveillance Agency (ANVISA).
There were no complications during the procedure, 
and control ventriculography showed no residual shunt 
(Figure 1). The patient remained asymptomatic after 
the procedure and was discharged within 48 hours. In the 
follow-up of nine months, the patient was asymptomatic, 
with significant improvement in functional class (NYHA class 
I), and control echocardiogram showed normal LVEF without 
evidence of residual shunt.
Discussion
In our case of post-AMI VSD closed percutaneously with 
prosthesis CERA, the patient had shown good immediate 
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which may result in subsequent abrupt expansion of the 
defect, with subsequent residual shunt. Obviously, the surgical 
results are better when you expect the healing of myocardial 
infarction (four to six weeks)3,5,7, but these findings only feature 
a selection bias (more severe cases die earlier), and the official 
recommendation of all current guidelines on the subject is the 
correction of the defect as soon as possible after diagnosis2.
Since the introduction of percutaneous closure of VSD7, 
several series have been reported, being initially used only 
for patients with VSD in sub-acute or chronic stage, or for 
patients with residual shunt after operation5. Later, Thiele et al3 
clinical improvement and in the follow-up of nine months. 
The VSD occurring after AMI is an event with high morbidity 
and mortality, especially in patients who develop cardiogenic 
shock and those not subject to surgical closure of the deffect1,3,4. 
However, this type of treatment still presents success rates of 
less than ideal, especially when performed in patients with high 
operative risk and / or unfavorable anatomy4.
Although surgical treatment is still considered the treatment 
of choice for correction of post-AMI VSD2, we have the fact 
that the septal branches are exposed to shear stress and the 
removal of necrotic tissue, soon after the occurrence of VSD, 
Figure 1 - Left ventriculography in hepatoclavicular projection showing: (A) ventricular septal defect (VSD)-type single muscle in the middle of the septum with a 
minimum diameter of 5 mm and a significant left-right flow (white arrow) (B) Percutaneous implantation of prosthesis CERA (white arrow) for closure of the VSD, (C) 
Control ventriculography demonstrating device well positioned with a minimum residual flow by the mesh of the prosthesis (white arrow).
Figure 2 - Prosthesis CERA of muscular ventricular septal defect. Prosthesis made of fine mesh of nitinol with two discs connected by a central waist of 7 mm in length. 
Internally, we note the patches of ultrathin polyester (ePTFE). A steel release cable connects to the right disk by a screw mechanism.
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published the first experience with the procedure performed 
in acute patients including cardiogenic shock, the survival rate 
at 30 days was 35%, reaching 12% in those with cardiogenic 
shock (p <0.001). In addition, 41% of patients had residual 
shunt, left ventricular rupture or embolization of the device 
in follow-up.
Most case and series reports in the literature evaluating 
the percutaneous closure of VSD in the context of AMI used 
the Amplatzer® septal occluder (AGA Medical Corporation, 
Plymouth, MN, USA)3,5. However, today many other prostheses 
have been tested as alternatives to Amplatzer® prostheses 
for septal defect closure, including the prosthesis CERA, 
whose characteristics were already described. Important to 
emphasize that these characteristics prevent direct contact 
of nitinol with the blood, promote tissue growth and reduce 
the risk of formation of thrombus6.
In this case, the defect was small (5 mm) and located in the 
muscle, with description of spontaneous closure of VSD after 
AMI with such characteristics8. However, our patient presented 
about five to six weeks of development of AMI and had an 
unfavorable clinical evolution, with progressive worsening of 
symptoms, the option for the correction of the defect resulted 
in complete remission of symptoms.
Conclusion
It is concluded that, despite surgical treatment remains 
the treatment of choice in patients with VSD after AMI, the 
percutaneous procedure may be an option, especially in patients 
with high operative risk and / or unfavorable anatomy for surgery.
Potential Conflict of Interest
No potential conflict of interest relevant to this article 
was reported.
Sources of Funding
There were no external funding sources for this study.
Study Association
This study is not associated with any post-graduation 
program.
e114
